ABCG2: Recent discovery of potent and highly selective inhibitors

Future Medicinal Chemistry

Volumn 5, Issue 9, 2013, Pages 1037-1045

  Lecerf Schmidt, Florine ^a   Peres, Basile ^a   Valdameri, Glaucio ^b,c   Gauthier, Charlotte ^b   Winter, Evelyn ^b   Payen, Léa ^b,d,e   Di Pietro, Attilio ^b   Boumendjel, Ahcène ^a  

^a UNIV GRENOBLE ALPES   (France)

^b UNIVERSITÉ LYON 1   (France)

^c FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^d CENTRE LÉON BÉRARD   (France)

^e HOSPICES CIVILS DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,4,6,7,12,12A OCTAHYDRO 6 ISOBUTYL 9 METHOXY 1,4 DIOXOPYRAZINO[1',2':1,6]PYRIDO[3,4 B]INDOLE 3 PROPANOIC ACID TERT BUTYL ESTER; BREAST CANCER RESISTANCE PROTEIN; CHALCONE DERIVATIVE; CHROMONE DERIVATIVE; CYCLOSPORIN; ELACRIDAR; MITOXANTRONE; RESERPINE; RESVERATROL; TARIQUIDAR;

BINDING AFFINITY; BREAST CANCER; CHEMICAL MODIFICATION; CONFORMATIONAL TRANSITION; CYTOTOXICITY; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORNER WADSWORTH EMMONS REACTION; HUMAN; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; TANDEM MASS SPECTROMETRY;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CHALCONES; CHROMONES; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; QUINOLINES; STILBENES;

EID: 84878737464     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.71     Document Type: Review

References (54)

1. Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22(47), 7340-7358 (2003).
2. Natarajan K, Xie Y, Baer MR, Ross DD. Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem. Pharmacol. 83(8), 1084-1103 (2012).
3. Ni Z, Bikadi Z, Rosenberg MF, Mao Q. Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Curr. Drug. Metab. 11(7), 603-617 (2010).
4. Poguntke M, Hazai E, Fromm MF, Zolk O. Drug transport by breast cancer resistance protein. Expert Opin. Drug Metab. Toxicol. 6(11), 1363-1384 (2010).
5. Loscher W, Potska H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat. Rev. Neurosci. 6(8), 591-602 (2005).
6. Agarwal S, Sane R, Gallardo JL, Ohlfest JR, Elmquist WF. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J. Pharmacol. Exp. Ther. 334(1), 147-155 (2010).
7. Zamek-Gliszczynski MJ, Nezasa K, Tian X, et al. The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice. Mol. Pharmacol. 70(6), 2127-2133 (2006).
8. Breedveld P, Pluim D, Cipriani G, et al. The effect of BCRP1 (ABCG2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res. 65(7), 2577-2582 (2005).
9. Breedveld P, Beijnen JH, Schellens JH. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol. Sci. 27(1), 17-24 (2006).
10. Poller B, Iusuf D, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics. Drug. Metab. Dispos. 39(5), 729-735 (2011).
11. Schnepf R, Zolk O. Effect of the ATP-binding cassette transporter ABCG2 on pharmacokinetics: experimental findings and clinical implications. Expert Opin. Drug Metab. Toxicol. 9(3), 287-306 (2013).
12. Marchetti S, Pluim D, van Eijndhoven M, et al. Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA. Invest. New Drugs (2013) (In Press).
13. Elkind NB, Szentpetery Z, Apati A, et al. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res. 65(5), 1770-1777 (2005).
14. Nagashima S, Soda H, Oka M, et al. BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer. Cancer Chemother. Pharmacol. 58(5), 594-600 (2006).
15. Lopez JP, Wang-Rodriguez J, Chang C, et al. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines. Arch. Otolaryngol. Head Neck Surg. 133(10), 1022-1027 (2007).
16. Lemos C, Jansen G, Peters GJ. Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors. Br. J. Cancer, 98(5), 857-862 (2008).
17. Boumendjel A, Macalou S, Valdameri G, et al. Targeting the multidrug ABCG2 transporter with f lavonoidic inhibitors: in vitro optimization and in vivo validation. Curr. Med. Chem. 18(22), 3387-3401 (2011).
18. Minocha M, Khurana V, Qin B, Pal D, Mitra AK. Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated eff lux with m-TOR inhibitors. Int. J. Pharm. 434(1-2), 306-314 (2012).
19. Galimberti S, Guerrini F, Palumbo GA, et al. Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients. Leuk. Res. 28(4), 367-372 (2004).
20. Maliepaard M, van Gastelen MA, de Jong LA, et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res. 59(18), 4559-4563 (1999).
21. Robey RW, Medina-Perez WY, Nishiyama K, et al. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in f lavopiridol-resistant human breast cancer cells. Clin. Cancer Res. 7(1), 145-152 (2001).
22. Su Y, Lee SH, Sinko PJ. Inhibition of eff lux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: evidence for multifactorial multidrug resistance. Eur. J. Pharm. Sci. 29(2), 102-110 (2006).
23. Wang X, Furukawa T, Nitanda T, et al. Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol. Pharmacol. 63(1), 65-72 (2003).
24. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5(3), 219-234 (2006).
25. Pusztai L, Wagner P, Ibrahim N, et al. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 104(4), 682-691 (2005).
26. Arnaud O, Boumendjel A, Gèze A, et al. The acridone derivative MBLI-87 sensitizes breast cancer resistance protein-expressing xenografts to irinotecan. Eur. J. Cancer 47(4), 640-648 (2011).
27. Leggas M, Panetta JC, Zhuang Y, et al. Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Res. 66(9), 4802-4807 (2006).
28. Robey RW, Ierano C, Zhan Z, Bates SE. The challenge of exploiting ABCG2 in the clinic. Curr. Pharm. Biotechnol. 12(4), 595-608 (2011).
29. Pick A, Müller H, Wiese M. Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2). Bioorg. Med. Chem. 16(17), 8224-8236 (2008).
30. Rabindran SK, He H, Singh M, et al. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res. 58(24), 5850-5858 (1998).
31. van Loevezijn A, Allen JD, Schinkel AH, Koomen GJ. Inhibition of BCRP-mediated drug eff lux by fumitremorgin-type indolyl diketopiperazines. Bioorg. Med. Chem. Lett. 11(1), 29-32 (2001).
32. Allen JD, van Loevezijn A, Lakhai JM, et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol. Cancer Ther. 1(6), 417-425 (2002).
33. Woehlecke H, Osada H, Herrmann A, Lage H. Reversal of breast cancer resistance protein-mediated drug resistance by tryprostatin A. Int. J. Cancer 107(5), 721-728 (2003).
34. Lemos C, Jansen G, Peters GJ. Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors. Br. J. Cancer 98(5), 857-862 (2008).
35. Ahmed-Belkacem A, Macalou S, Borrelli F, et al. Nonprenylated rotenoids, a new class of potent breast cancer resistance protein inhibitors. J. Med. Chem. 50(8), 1933-1938 (2007).
36. Nakata R, Takahashi S, Inoue H. Recent advances in the study on resveratrol. Biol. Pharm. Bull. 35(3), 273-279 (2012).
37. Breedveld P, Pluim D, Cipriani G, et al. The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan and resveratrol in in vitro drug transport models. Mol. Pharmacol. 71(1), 240-249 (2007).
38. Cooray H, Janvilisri T, Van Veen HW, Hladky SB, Barrand MA, Interaction of the breast cancer resistance protein with plant polyphenols. Biochem. Biophys. Res. Commun. 317(1), 269-275 (2004).
39. Valdameri G, Pereira Rangel L, Spatafora C, et al. Methoxy stilbenes as potent, specific, untransported, and noncytotoxic inhibitors of breast cancer resistance protein. ACS Chem. Biol. 7(2), 322-330 (2012).
40. Robey RW, Honjo Y, van de Laar A, et al. A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). BBA-biomembranes 1512(2), 171-182 (2001).
41. Kühnle M, Egger M, Müller C, et al. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar. J. Med. Chem. 52(4), 1190-1197 (2009).
42. Valdameri G, Genoux-Bastide E, Peres B, et al. Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein. J. Med. Chem. 55(2), 966-970 (2012).
43. Hadjeri M, Barbier M, Ronot X, Mariotte AM, Boumendjel A, Boutonnat J. Modulation of P-glycoprotein-mediated multidrug resistance by f lavonoid derivatives and analogues. J. Med. Chem. 46(11), 2125-2131 (2003).
44. Valdameri G, Genoux-Bastide E, Gauthier C, et al. 6-halogenochromones bearing tryptamine: one-step access to potent and highly selective inhibitors of breast cancer resistance protein. ChemMedChem 7(7), 1177-1180 (2012).
45. Boumendjel A, Ronot X, Boutonnat J. Chalcones derivatives acting as cell cycle blockers: potential anticancer drugs? Curr. Drug Targets 10(4), 363-371 (2009).
46. Bois F, Beney C, Boumendjel A, Mariotte AM, Conseil G, Di Pietro A. Halogenated chalcones with high-affinity binding to P-glycoprotein: potential modulators of multidrug resistance. J. Med. Chem. 41(21), 4161-4164 (1998).
47. Han Y, Riwanto M, Go ML, Ee PL. Modulation of breast cancer resistance protein (BCRP/ABCG2) by non-basic chalcone analogues. Eur. J. Pharm. Sci. 35(1-2), 30-41 (2008).
48. Liu XL, Tee HW, Go ML. Functionalized chalcones as selective inhibitors of P-glycoprotein and breast cancer resistance protein. Bioorg. Med. Chem. 16(1), 171-180 (2008).
49. Juvale K, Pape VF, Wiese M. Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein. Bioorg. Med. Chem. 20(1), 346-355 (2012).
50. Valdameri G, Gauthier C, Terreux R, et al. Investigation of chalcones as selective inhibitors of the breast cancer resistance protein: critical role of methoxylation in both inhibition potency and cytotoxicity. J. Med. Chem. 55(7), 3193-3200 (2012).
51. Fasinu P, Pillay V, Ndesendo VMK, du Toit LC, Choonara YE. Diverse approaches for the enhancement of oral drug bioavailability. Biopharm. Drug Dispos. 32(4), 185-209 (2011).
52. Yang S, Gursoy RN, Lambert G, Benita S. Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. Pharm. Res. 21(2), 261-270 (2004).
53. Breedveld P, Beijnen JH, Schellens JHM. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol. Sci. 27(1), 17-24 (2006).
54. Woo JS, Lee CH, Shim CK, Hwang S. Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. Pharm. Res. 20(1), 24-30 (2003).